Home · Stock · BIIB

BIIB Biogen Inc

Which ETFs hold BIIB? Biogen Inc is held by 2 funds tracked by ETFpeek.

Held by 2 funds todayData as of 31 Aug 2026
HealthcareDrug Manufacturers - General
$218.43
+49.0% 1y
$138.0052-week range$230.49
Market cap
$32.5B
P/E
38.8
3-month
+9.7%
CEO
Mr. Christopher A. Viehbacher
Revenue · last 4 qtrs (+3.4% YoY)

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Provider

Currently Held By

VANGUARD
VOO
Weight in fund0.05%
Shares held3,923,451
Market value$850.0M
View fund →
SMARTSHARES
USF
Smart US 500 ETF
via VOO
Weight in fund0.05%
Shares held—
Market value$606K NZD
View fund →
Not held by the selected provider.
last 90 days
No notable insider activity in the last 90 days. Show all 3 trades
Net flow (90d):−$2K (2 without value)·2 BUY / 1 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
2 Oct 2026
Sean Godbout
VP, Chief Accounting Officer & Global Corporate Controller
BUYOption Exercise27—0
2 Oct 2026
Sean Godbout
VP, Chief Accounting Officer & Global Corporate Controller
SELLVested (RSU)8$2K0
1 Oct 2026
Sean Godbout
VP, Chief Accounting Officer & Global Corporate Controller
BUYVested (RSU)985—0
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
0 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
No trades recorded yet.
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds